Researchers suggest that the benefits of psychedelic treatment are mediated by a reduction in death anxiety and existential distress.
The serotonin 2A receptor is a major player in the psychedelic response, but it may not be the only one involved.
Despite differing pharmacodynamics, ketamine and serotonergic psychedelics may share downstream effects crucial to their rapid and sustained antidepressant activity.
Ketamine and psilocybin both exert rapid antidepressant effects. Could these effects be explained by a common mechanism that promotes neurogenesis?
Changes in structural neuroplasticity start within 24 hours, are enduring, and may not be solely dependent on 5-HT2A.
5-HT1AR vs. 5-HT2AR signaling and the treatment of depression.
Researchers see value in a naturalistic approach to psychedelic studies.
A deep dive into the strengths and limitations of the trial.
Was psilocybin really effective for treating depression?
Terminal patients are learning to live, not just preparing to die.